Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

FDA-approved disulfiram inhibits the NLRP3 inflammasome by regulating NLRP3 palmitoylation

Cell Reports(2024)10.1016/j.celrep.2024.114609Source: DataRank Database

FDA-approved disulfiram inhibits the NLRP3 inflammasome by regulating NLRP3 palmitoylation is a research paper published in Cell Reports (2024). On theSindex it has a DataRank of 0. It has been cited 46 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access46 citations

Download PDF

Cite:

Linked data & code

pxd

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 7.85)OA: goldTopics (48)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Joseph M. Pickard ORCID,Gabriel Núñez ORCID,Jie Xu ORCID

Live enrichment

PubMed:39116210 PMC:PMC11398858 OpenAlex:https://openalex.org/W4401394033

National Institutes of Health

Grant: R37AI063331

NCI NIH HHS

Grant: P30 CA046592

National Institutes of Health

Grant: 5R37AI063331-20

Cryopyrin/NLRP3 Signaling in Inflammation and Innate Immunity

FWCI

7.85

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttp://www.cell.com/article/S2211124724009598/pdf

publisherhttp://www.cell.com/article/S2211124724009598/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2211124724009598?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2211124724009598?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.celrep.2024.114609

Fields of Study

Inflammasome and immune disordersHeme Oxygenase-1 and Carbon Monoxide03 medical and health sciences0302 clinical medicine

MeSH Terms

PyroptosisNLR Family, Pyrin Domain-Containing 3 ProteinAnimalsDisulfiramHumansMice, Inbred C57BLUnited StatesUnited States Food and Drug AdministrationDrug ApprovalCaspase 1MiceLipoylationHEK293 CellsInflammasomes

Keywords

InflammasomeDisulfiramPharmacologyPyroptosisNLRC4Caspase 1MedicineAIM2DrugPalmitoylationChemistryInflammationCysteineImmunologyBiochemistryNlrp3Gasdermin DCp: ImmunologyInflammasomesUnited States Food and Drug AdministrationLipoylationArticleUnited StatesMice, Inbred C57BLMiceHEK293 CellsNLR Family, Pyrin Domain-Containing 3 ProteinAnimalsHumansDrug Approval

Sustainable Development Goals

SDG 0: Zero hunger

FDA-approved disulfiram inhibits the NLRP3 inflammasome by regulating NLRP3 palmitoylation

FAIR Checklist

Authors (3)

Funding (3 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)